Revvity Raises Outlook as Life Sciences Outpaces

Life sciences tool buyers and diagnostics suppliers should note the growth gap between segments and the exit from China IDX.

Updated on Nov. 3, 2026 in Healthcare

Revvity Raises Outlook as Life Sciences Outpaces

Revvity reported third-quarter 2026 revenue of $728.9 million, up from $698.9 million a year earlier, and raised its full-year pro forma adjusted EPS outlook. The company is divesting its China IDX Immunodiagnostics business, which is excluded from its pro forma guidance.

Why it matters

Revvity's pro forma guidance strips out China IDX, a business that made up about 6% of fiscal 2025 revenue, so the raised outlook reflects the continuing business rather than the full company. For operators in life sciences and diagnostics supply, the quarter shows Life Sciences growing while Diagnostics declined.

Revvity's third-quarter pro forma revenue grew 7% to $709.6 million, and Life Sciences revenue rose to $380 million from $343 million. The company projects about $2.86 billion in 2026 pro forma revenue and pro forma adjusted EPS between $5.40 and $5.45. Diagnostics revenue declined in the quarter, though the source does not give the dollar figure.

The players

Revvity

A life sciences and diagnostics company whose Life Sciences and Diagnostics businesses supply laboratory and clinical testing products to research and healthcare customers.

The details

Revvity's pro forma figures exclude China IDX, its Immunodiagnostics business in China, which is being divested. The company expects to complete that sale by the end of 2027, subject to customary conditions and regulatory approvals. Because China IDX is excluded, the pro forma adjusted EPS of $1.37 for the quarter differs from the $1.38 adjusted EPS reported for continuing operations.

The third quarter ended Oct. 4, 2026.
Revvity raised its full-year pro forma adjusted EPS outlook in 2026.
The China IDX divestiture is expected to be completed by the end of 2027.

Market Landscape

Revvity's China IDX divestiture narrows its exposure to China, a business that accounted for about 6% of fiscal 2025 revenue. The quarter's results show the company's Life Sciences segment outpacing Diagnostics, a split that shapes how the company is positioned against peers in the life sciences tools market.

Operators in healthcare supply and laboratory purchasing should note that Life Sciences demand is currently stronger than Diagnostics demand at Revvity. Procurement teams that rely on the company's Diagnostics products may want to monitor pricing and availability as the China IDX sale proceeds.

The takeaway

The operating signal is that Revvity's growth is coming from its Life Sciences segment while Diagnostics softens, and its outlook excludes China IDX. Operators tracking supplier risk should watch the China IDX divestiture closing and Revvity's Diagnostics results in its next quarterly filing.